NanoLogix Cooperative Projects Update For EPA and University of Texas Health Science Center Houston
14 December 2010 - 12:00AM
Business Wire
NanoLogix (PINK OTC Markets: NNLX), an innovator in the
accelerated detection and identification of microorganisms,
announces the current 300 patient trial of NanoLogix GBS (Group B
Streptococcus) Quick Tests is ongoing at the University of Texas
Health Science Center (UTHSC) in Houston. NanoLogix anticipates
initial filings for GBS Quick-Test FDA approval following final
publication of the GBS trial results. In addition, this month UTHSC
Houston plans to expand its evaluation of NanoLogix Quick Tests,
concurrent with the GBS trial, to include the superbug MRSA
(formally known as Methicillin-resistant Staphylococcus aureus),
with E.Coli and Pseudomonas to follow in early 2011. For further
information on the GBS trial please visit the UTHSC - Houston
Newsroom at:
http://www.uthouston.edu/media/newsreleases/nr2010/index.htm?id=2434326
NanoLogix Technology Focused on Domination of $150 Million
U.S. Ob/Gyn GBS Testing Market
NanoLogix seeks to lead innovation in the market of GBS Ob/Gyn
testing, which in the U.S. is valued at approximately $150 million
annually. Initial results from UTHSC Houston last spring show the
GBS Quick Tests returned reliable results in approximately four
hours. With the current standard of 48-72 hours, this is a markedly
significant reduction in testing time. Today’s GBS strains are
resistant to ampicillin and amoxicillin and by improving standard
detection speed, NanoLogix and the physicians at UTHSC Houston hope
to dramatically reduce the overuse of antibiotics in pregnant women
and contribute to the fight against GBS antibiotic resistance.
NanoLogix EPA CRADA To Continue Until 2012
NanoLogix is currently in the first phase of its work to assist
the US Environmental Protection Agency (EPA) in the development of
a comprehensive water quality test kit for use with surface and
source waters. NanoLogix and the EPA have a Cooperative Research
and Development Agreement (CRADA) with runs through 2012. For
additional information please visit the internal news update
archive at the EPA's Microbiological and Chemical Exposure
Assessment Research Division (MCEARD):
http://www.epa.gov/microbes/mceardnewsarchive.html
NanoLogix Cincinnati Laboratory
NanoLogix is pleased to announce an operations evolution in its
BioStart Cincinnati laboratory designed to better serve the needs
of its clients, customers, and partners. The company has added new
equipment and appointed Ahmer Kodvowala, MS, MBA as Director of
Laboratory Operations. Hilda Diaz, MS, will continue to serve as
Senior Researcher. Joining the laboratory as the new research
assistant is Michael Sube, BA. NanoLogix doubled the size of its
laboratory facility in July 2010 and added additional office space
at that time. The current changes are in keeping with established
expansion plans.
Dr. Sergey Gazenko has left the company for personal reasons. He
is the author of 2 of NanoLogix 34 granted patents and 3 patents
pending. Dr. Gazenko will provide consulting services to NanoLogix
as needed.
About NanoLogix, Inc.
NanoLogix is a biotechnology company focused primarily on rapid
diagnostics. Its products offer accelerated detection and
identification of microorganisms. Along with medical and homeland
security applications, NanoLogix technology is applicable in
pharmaceutical, industrial, veterinary and environmental testing.
Patents granted to NanoLogix can be used in the areas of applied
microbiology, soil microbiology and bioremediation, microbial
physiology, molecular biology, pharmacology, pharmaco-kinetics, and
antibiotic sensitivity.
For more information visit www.nanologix.com.
This press release contains statements, which may constitute
"forward-looking statements" within the meaning of the Securities
Act of 1933 and the Securities Exchange Act of 1934, as amended by
the Private Securities Litigation Reform Act of 1995. Those
statements include statements regarding the intent, belief or
current expectations of NanoLogix, Inc., and members of its
management as well as the assumptions on which such statements are
based. Prospective investors are cautioned that any such
forward-looking statements are not guarantees of future performance
and involve risks and uncertainties, and that actual results may
differ materially from those contemplated by such forward-looking
statements. The Company undertakes no obligation to update or
revise forward-looking statements to reflect changed assumptions,
the occurrence of unanticipated events or changes to future
operating results.
NanoLogix (CE) (USOTC:NNLX)
Historical Stock Chart
From Jun 2024 to Jul 2024
NanoLogix (CE) (USOTC:NNLX)
Historical Stock Chart
From Jul 2023 to Jul 2024